163 related articles for article (PubMed ID: 21504156)
1. Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
Ceccarelli SM; Chomienne O; Gubler M; Arduini A
J Med Chem; 2011 May; 54(9):3109-52. PubMed ID: 21504156
[No Abstract] [Full Text] [Related]
2. Aminocarnitine ureidic derivatives as inhibitors of carnitine palmitoyltransferase I.
Tassoni E; Conti R; Gallo G; Vincenti S; Dell'Uomo N; Mastrofrancesco L; Ricciolini R; Cabri W; Carminati P; Giannessi F
ChemMedChem; 2010 May; 5(5):666-9. PubMed ID: 20232438
[No Abstract] [Full Text] [Related]
3. Molecular basis of hepatic carnitine palmitoyltransferase I deficiency.
IJlst L; Mandel H; Oostheim W; Ruiter JP; Gutman A; Wanders RJ
J Clin Invest; 1998 Aug; 102(3):527-31. PubMed ID: 9691089
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a long-chain carbamoyl aminocarnitine derivative, a reversible carnitine palmitoyltransferase inhibitor with antiketotic and antidiabetic activity.
Giannessi F; Pessotto P; Tassoni E; Chiodi P; Conti R; De Angelis F; Dell'Uomo N; Catini R; Deias R; Tinti MO; Carminati P; Arduini A
J Med Chem; 2003 Jan; 46(2):303-9. PubMed ID: 12519067
[TBL] [Abstract][Full Text] [Related]
5. Carnitine analogues and carnitine palmitoyltransferases.
Murthy MS; Ramsay RR; Pande SV
Biochem Soc Trans; 1990 Aug; 18(4):604-5. PubMed ID: 2276460
[No Abstract] [Full Text] [Related]
6. The crystal structure of carnitine palmitoyltransferase 2 and implications for diabetes treatment.
Rufer AC; Thoma R; Benz J; Stihle M; Gsell B; De Roo E; Banner DW; Mueller F; Chomienne O; Hennig M
Structure; 2006 Apr; 14(4):713-23. PubMed ID: 16615913
[TBL] [Abstract][Full Text] [Related]
7. Stereoisomeric acylamidomorpholinium carnitine analogues: selective inhibitors of carnitine palmitoyltransferase I and II.
Savle PS; Pande SV; Lee TS; Gandour RD
Bioorg Med Chem Lett; 1999 Nov; 9(21):3099-102. PubMed ID: 10560732
[TBL] [Abstract][Full Text] [Related]
8. Structural model of carnitine palmitoyltransferase I based on the carnitine acetyltransferase crystal.
Morillas M; López-Viñas E; Valencia A; Serra D; Gómez-Puertas P; Hegardt FG; Asins G
Biochem J; 2004 May; 379(Pt 3):777-84. PubMed ID: 14711372
[TBL] [Abstract][Full Text] [Related]
9. Modulation of carnitine palmitoyltransferase-1 for the treatment of obesity.
Kuhajda FP; Ronnett GV
Curr Opin Investig Drugs; 2007 Apr; 8(4):312-7. PubMed ID: 17458181
[TBL] [Abstract][Full Text] [Related]
10. [L-propionylcarnitine taurine amide induces the metabolic recovery of the isolated postischemic rat heart].
Lazzarino G; Corsico N; Tavazzi B; di Pierro D; Arrigoni-Martelli E; Giardina B
Cardiologia; 1992 Oct; 37(10):715-7. PubMed ID: 1296879
[TBL] [Abstract][Full Text] [Related]
11. Carnitine palmitoyltransferase-I, a new target for the treatment of heart failure: perspectives on a shift in myocardial metabolism as a therapeutic intervention.
Mengi SA; Dhalla NS
Am J Cardiovasc Drugs; 2004; 4(4):201-9. PubMed ID: 15285695
[TBL] [Abstract][Full Text] [Related]
12. Carnitine palmitoyltransferase 2: analysis of membrane association and complex structure with a substrate analog.
Rufer AC; Lomize A; Benz J; Chomienne O; Thoma R; Hennig M
FEBS Lett; 2007 Jul; 581(17):3247-52. PubMed ID: 17585909
[TBL] [Abstract][Full Text] [Related]
13. Astaxanthin improves muscle lipid metabolism in exercise via inhibitory effect of oxidative CPT I modification.
Aoi W; Naito Y; Takanami Y; Ishii T; Kawai Y; Akagiri S; Kato Y; Osawa T; Yoshikawa T
Biochem Biophys Res Commun; 2008 Feb; 366(4):892-7. PubMed ID: 18082622
[TBL] [Abstract][Full Text] [Related]
14. Lack of association of CPT1A polymorphisms or haplotypes on hepatic lipid content or insulin resistance in Japanese individuals with type 2 diabetes mellitus.
Hirota Y; Ohara T; Zenibayashi M; Kuno S; Fukuyama K; Teranishi T; Kouyama K; Miyake K; Maeda E; Kasuga M
Metabolism; 2007 May; 56(5):656-61. PubMed ID: 17445541
[TBL] [Abstract][Full Text] [Related]
15. A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels.
Stefanovic-Racic M; Perdomo G; Mantell BS; Sipula IJ; Brown NF; O'Doherty RM
Am J Physiol Endocrinol Metab; 2008 May; 294(5):E969-77. PubMed ID: 18349115
[TBL] [Abstract][Full Text] [Related]
16. Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer.
Qu Q; Zeng F; Liu X; Wang QJ; Deng F
Cell Death Dis; 2016 May; 7(5):e2226. PubMed ID: 27195673
[TBL] [Abstract][Full Text] [Related]
17. Functional studies of yeast-expressed human heart muscle carnitine palmitoyltransferase I.
Zhu H; Shi J; de Vries Y; Arvidson DN; Cregg JM; Woldegiorgis G
Arch Biochem Biophys; 1997 Nov; 347(1):53-61. PubMed ID: 9344464
[TBL] [Abstract][Full Text] [Related]
18. Cloning and expression of the liver and muscle isoforms of ovine carnitine palmitoyltransferase 1: residues within the N-terminus of the muscle isoform influence the kinetic properties of the enzyme.
Price NT; Jackson VN; van der Leij FR; Cameron JM; Travers MT; Bartelds B; Huijkman NC; Zammit VA
Biochem J; 2003 Jun; 372(Pt 3):871-9. PubMed ID: 12662154
[TBL] [Abstract][Full Text] [Related]
19. Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure.
Lionetti V; Linke A; Chandler MP; Young ME; Penn MS; Gupte S; d'Agostino C; Hintze TH; Stanley WC; Recchia FA
Cardiovasc Res; 2005 Jun; 66(3):454-61. PubMed ID: 15914110
[TBL] [Abstract][Full Text] [Related]
20. Immunodetection of rat Walker 256 tumour mitochondrial carnitine palmitoyltransferase I and II: evidence for the control of CPT II expression by insulin.
Colquhoun A; Curi R
Biochem Mol Biol Int; 1996 Feb; 38(1):171-4. PubMed ID: 8932531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
